HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 study

[Guest guest]

J Med Virol. 2004 Sep;74(1):34-40.

HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative

pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 study.

Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F,

Rouzioux C.

CeDReS, CHU de Treichville, Abidjan, Cote d'Ivoire.

A retrospective survey estimating the prevalence of hepatitis viruses B

(HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant

women (501 diagnosed as HIV-1 positive and 501 HIV-1 negative) participating

in a clinical trial program conducted in Abidjan, Cote d'Ivoire (West

Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if

positive, HBe antigen/anti-HBe antibodies and HBV DNA. Two third generation

(G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All

anti-HCV antibody-positive sera were assessed further with supplementary

assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also

determined. HBsAg was found in a similar proportion among HIV-positive

(45/499, 9.0%, 95% confidence interval [95% CI], 6.6-11.9) and HIV-negative

(40/498, 8.0%, 95% CI, 5.8-10.8) women (P = 0.58). The diagnosis of chronic

hepatitis B, based on HBV DNA positive results, was more frequent in

HIV-positive women (26.7%), compared to HIV-negative women (9.4%) (P =

0.06). In the case of hepatitis C infection, after supplementary testing

allowing the elimination of frequent false-positive screening results, a

prevalence rate of about 1% was found, both in HIV-positive (6/501, 1.2%,

95% CI, 0.44-2.59) and HIV-negative (4/501, 0.8%, 95% CI, 0.22-2.03) women

(P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA,

eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative

high frequency of HIV/HBV coinfection in Cote d'Ivoire emphasises the need

for monitoring the risk of hepatotoxicity by antiretroviral therapy in such

patients. We propose an accurate and cost-efficient algorithm for HCV

diagnosis in Africa. J. Med. Virol. 74:34-40, 2004. Copyright 2004

Wiley-Liss, Inc.

PMID: 15258966 [PubMed - in process]

[Guest guest]

J Med Virol. 2004 Sep;74(1):34-40.

HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative

pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 study.

Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F,

Rouzioux C.

CeDReS, CHU de Treichville, Abidjan, Cote d'Ivoire.

A retrospective survey estimating the prevalence of hepatitis viruses B

(HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant

women (501 diagnosed as HIV-1 positive and 501 HIV-1 negative) participating

in a clinical trial program conducted in Abidjan, Cote d'Ivoire (West

Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if

positive, HBe antigen/anti-HBe antibodies and HBV DNA. Two third generation

(G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All

anti-HCV antibody-positive sera were assessed further with supplementary

assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also

determined. HBsAg was found in a similar proportion among HIV-positive

(45/499, 9.0%, 95% confidence interval [95% CI], 6.6-11.9) and HIV-negative

(40/498, 8.0%, 95% CI, 5.8-10.8) women (P = 0.58). The diagnosis of chronic

hepatitis B, based on HBV DNA positive results, was more frequent in

HIV-positive women (26.7%), compared to HIV-negative women (9.4%) (P =

0.06). In the case of hepatitis C infection, after supplementary testing

allowing the elimination of frequent false-positive screening results, a

prevalence rate of about 1% was found, both in HIV-positive (6/501, 1.2%,

95% CI, 0.44-2.59) and HIV-negative (4/501, 0.8%, 95% CI, 0.22-2.03) women

(P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA,

eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative

high frequency of HIV/HBV coinfection in Cote d'Ivoire emphasises the need

for monitoring the risk of hepatotoxicity by antiretroviral therapy in such

patients. We propose an accurate and cost-efficient algorithm for HCV

diagnosis in Africa. J. Med. Virol. 74:34-40, 2004. Copyright 2004

Wiley-Liss, Inc.

PMID: 15258966 [PubMed - in process]

[Guest guest]

J Med Virol. 2004 Sep;74(1):34-40.

HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative

pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 study.

Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F,

Rouzioux C.

CeDReS, CHU de Treichville, Abidjan, Cote d'Ivoire.

A retrospective survey estimating the prevalence of hepatitis viruses B

(HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant

women (501 diagnosed as HIV-1 positive and 501 HIV-1 negative) participating

in a clinical trial program conducted in Abidjan, Cote d'Ivoire (West

Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if

positive, HBe antigen/anti-HBe antibodies and HBV DNA. Two third generation

(G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All

anti-HCV antibody-positive sera were assessed further with supplementary

assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also

determined. HBsAg was found in a similar proportion among HIV-positive

(45/499, 9.0%, 95% confidence interval [95% CI], 6.6-11.9) and HIV-negative

(40/498, 8.0%, 95% CI, 5.8-10.8) women (P = 0.58). The diagnosis of chronic

hepatitis B, based on HBV DNA positive results, was more frequent in

HIV-positive women (26.7%), compared to HIV-negative women (9.4%) (P =

0.06). In the case of hepatitis C infection, after supplementary testing

allowing the elimination of frequent false-positive screening results, a

prevalence rate of about 1% was found, both in HIV-positive (6/501, 1.2%,

95% CI, 0.44-2.59) and HIV-negative (4/501, 0.8%, 95% CI, 0.22-2.03) women

(P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA,

eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative

high frequency of HIV/HBV coinfection in Cote d'Ivoire emphasises the need

for monitoring the risk of hepatotoxicity by antiretroviral therapy in such

patients. We propose an accurate and cost-efficient algorithm for HCV

diagnosis in Africa. J. Med. Virol. 74:34-40, 2004. Copyright 2004

Wiley-Liss, Inc.

PMID: 15258966 [PubMed - in process]

[Guest guest]

J Med Virol. 2004 Sep;74(1):34-40.

HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative

pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 study.

Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F,

Rouzioux C.

CeDReS, CHU de Treichville, Abidjan, Cote d'Ivoire.

A retrospective survey estimating the prevalence of hepatitis viruses B

(HBV) and C (HCV) was conducted on samples taken in 1,002 African pregnant

women (501 diagnosed as HIV-1 positive and 501 HIV-1 negative) participating

in a clinical trial program conducted in Abidjan, Cote d'Ivoire (West

Africa). Hepatitis B markers studied were HBs antigen (HBsAg), and if

positive, HBe antigen/anti-HBe antibodies and HBV DNA. Two third generation

(G3) HCV enzyme immunoassays (EIAs) were used for primary HCV screening. All

anti-HCV antibody-positive sera were assessed further with supplementary

assays (one another G3 EIA, RIBA 3.0, and HCV RNA). HCV genotypes were also

determined. HBsAg was found in a similar proportion among HIV-positive

(45/499, 9.0%, 95% confidence interval [95% CI], 6.6-11.9) and HIV-negative

(40/498, 8.0%, 95% CI, 5.8-10.8) women (P = 0.58). The diagnosis of chronic

hepatitis B, based on HBV DNA positive results, was more frequent in

HIV-positive women (26.7%), compared to HIV-negative women (9.4%) (P =

0.06). In the case of hepatitis C infection, after supplementary testing

allowing the elimination of frequent false-positive screening results, a

prevalence rate of about 1% was found, both in HIV-positive (6/501, 1.2%,

95% CI, 0.44-2.59) and HIV-negative (4/501, 0.8%, 95% CI, 0.22-2.03) women

(P = 0.53). Of the 10 samples confirmed positive and assessed for HCV RNA,

eight (80%) were viraemic and belonged to HCV genotypes 1 or 2. The relative

high frequency of HIV/HBV coinfection in Cote d'Ivoire emphasises the need

for monitoring the risk of hepatotoxicity by antiretroviral therapy in such

patients. We propose an accurate and cost-efficient algorithm for HCV

diagnosis in Africa. J. Med. Virol. 74:34-40, 2004. Copyright 2004

Wiley-Liss, Inc.

PMID: 15258966 [PubMed - in process]